The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia
Abstract
Background Many patients with coronary heart disease do not achieve recommended LDL-cholesterol levels, due to either intolerance or inadequate response to available lipid-lowering therapy. Microsomal triglyceride transfer protein (MTP) inhibitors might provide an alternative way to lower LDL-cholesterol levels. We tested the safety and LDL-cholesterol-lowering efficacy of an MTP inhibitor, AEGR-733 (Aegerion Pharmaceuticals Inc., Bridgewater, NJ), alone and in combination with ezetimibe.Methods We performed a multicenter, double-blind, 12-week trial, which included 84 patients with hypercholesterolemia. Patients were randomly assigned ezetimibe 10 mg daily (n = 29); AEGR-733 5.0 mg daily for the first 4 weeks, 7.5 mg daily for the second 4 weeks and 10 mg daily for the last 4 weeks (n = 28); or ezetimibe 10 mg daily and AEGR-733 administered with the dose titration described above (n = 28).Results Ezetimibe monotherapy led to a 20-22% decrease in LDL-cholesterol concentrations. AEGR-733 monotherapy led to a dose-dependent decrease in LDL-cholesterol concentration: 19% at 5.0 mg, 26% at 7.5 mg and 30% at 10 mg. Combined therapy produced similar but larger dose-dependent decreases (35%, 38% and 46%, respectively). The number of patients who discontinued study drugs owing to adverse events was five with ezetimibe alone, nine with AEGR-733 alone, and four with combined ezetimibe and AEGR-733. Discontinuations from AEGR-733 were due primarily to mild transaminase elevations.Conclusions Inhibition of LDL production with low-dose AEGR-733, either alone or in combination with ezetimibe, could be an effective therapeutic option for patients unable to reach target LDL-cholesterol levels.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a phase-3 study involving subjects with a high risk for cardiovascular events including those with heterozygous FH, administrating PCSK9 inhibitor once every two weeks decreased LDL-C levels by 70–75% with combination oral statins682, 683).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [683]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Self-citationExpert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Smith, S. C., Allen, J. K., Blair, S. N., Bonow, R. O., Brass, L. M., Fonarow, G. C., Grundy, S. M., Hiratzka, L. F., Jones, D. W., Krumholz, H. M., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.174516 · Cited by 2,102
Intensive Lifestyle Changes for Reversal of Coronary Heart Disease
Ornish, D. (1998) · JAMA · doi:10.1001/jama.280.23.2001 · Cited by 1,730
Svedlund, J., Sjödin, I., & Dotevall, G. (1988) · Digestive Diseases and Sciences · doi:10.1007/bf01535722 · Cited by 1,319
Stern, L., Iqbal, N., Seshadri, P., Chicano, K. L., Daily, D. A., McGrory, J., Williams, M., Gracely, E. J., & Samaha, F. F. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-10-200405180-00007 · Cited by 831 · cited 1×
“The decrease in HDL-cholesterol concentrations caused by MTP-inhibition might be attributable to at least three potential mechanisms: first, low-fat diets are known to reduce HDL-cholesterol levels”
BackgroundSelf-citationStem, L., Iqbal, N., Seshadri, P., & Chicano, K. L. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.07.103 · Cited by 629
Revicki, D. A., Wood, M., Wiklund, I. E., & Crawley, J. A. (1997) · Quality of Life Research · doi:10.1023/a:1008841022998 · Cited by 623
Research works printed but not linked: 1
- Zaiss S et al. (1999) BAY 13-9952, an inhibitor of the microsomal triglyceride transfer protein (MTP), inhibits atherosclerotic plaque formation in cholesterol-fed rabbits in spite of a concomitant reductio of vitamin E [Abstr]. Circulation. 100 (Suppl 1): 258
Cited by
Sorted by citations
Items 201–219 of 219
Novel therapeutic approaches to prevention and regression of atherosclerosis
Chyu, K., & Shah, P. K. (2012) · CRC Press eBooks · doi:10.3109/9781841848549.037
Molecular Mechanisms of Intracellular Apolipoprotein B100 Degradation
Rutledge, A. C. (2011) · TSpace (University of Toronto)
Novel therapies for dyslipidemia
Wierzbicki, A. S. (2013) · doi:10.2217/fmeb2013.13.9
Durlach, V. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30040-9
家族性高コレステロール血症（PCSK9阻害薬，MTP阻害薬）
小倉, 正. (2017) · 心臓 · doi:10.11281/shinzo.49.432
Kathiresan, S., & Rader, D. J. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-382227-7.00045-8
Self-citationLipoprotein (a): Principles from Bench to Bedside
Koschinsky, M. L., & Boffa, M. B. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_19
General Perspectives for the Treatment of Atherosclerosis
Gülcan, H. O., & Orhan, İ. E. (2020) · Letters in Drug Design & Discovery · doi:10.2174/1570180817999201016154400
(2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32831b7581
(2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328334096a
Toth, P. P. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_3
Research Progress of Application of Novel Li-pid-Regulating Drugs
商, 博. (2018) · Pharmacy Information · doi:10.12677/pi.2018.74014
小倉, 正., & 斯波真理子 (2018) · Journal of JCS Cardiologists · doi:10.1253/jjcsc.27.0_64
Cholesterol Absorption Inhibitors
Norato, G. D., & Catapano, A. L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00023-2
Moriarty, P. M., & Santos, R. D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00038-4
Brief Overview of Statins for Lowering Low-Density Lipid Cholesterol
唐, 素. (2024) · Pharmacy Information · doi:10.12677/pi.2024.135050
Jia, X., Liu, J., Jiang, W., Chang, L., Shen, X., Jiang, G., Li, X., Chi, C., Liu, W., & Zhang, D. (2024) · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · doi:10.1016/j.cbpa.2024.111763
Tang, X. L., Hooper, A. J., & Burnett, J. R. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2598458
Chemello, K. (2022) · theses.fr (ABES) · doi:10.70675/6f647f12za09bz494fzae02z9be71ebf2915
Metadata
- Authors
- Samaha, F. F., McKenney, J., Bloedon, L. T., Sasiela, W. J., & Rader, D. J.
- Affiliations
- Philadelphia VA Medical Center (US)
- Virginia Commonwealth University (US)
- University of Pennsylvania (US)
- Aegerion Pharmaceuticals (United States) (US)
- Corresponding author
- Samaha, Frederick F
- Venue
- Nature Clinical Practice Cardiovascular Medicine
- Published
- 2008-05-27
- Volume
- 5
- Issue
- 8
- Pages
- 497-505
- ISSN
- 1743-4297 (ISSN-L)
- 1743-4300
- OpenAlex
- W2046959088
- Cited by
- 220
- References
- 31
- Citations by year
- 2026: 2 · 2025: 8 · 2024: 11 · 2023: 4 · 2022: 11 · 2021: 5 · 2020: 4 · 2019: 7 · 2018: 10 · 2017: 8 · 2016: 15 · 2015: 18 · 2014: 29 · 2013: 27 · 2012: 23
- FWCI
- 13.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Clinical Practice Cardiovascular Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- microsomal triglyceride transfer protein, MTP inhibitors, ezetimibe, hypercholesterolemia, LDL cholesterol lowering, combination lipid-lowering therapy, dose titration, transaminase elevation, drug safety, coronary artery disease, statin intolerance, treatment response variability, triglyceride-rich lipoproteins
- MeSH terms
- Ezetimibe, Aged, Anticholesteremic Agents, Azetidines, Benzimidazoles, Carrier Proteins, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Microsomes, Middle Aged, Severity of Illness Index, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
